Zacks Investment Research
17 Jul 2026, 17:51 UTC · 1h ago
MRK Stock Jumps on FDA Nod for Cholesterol-Lowering Pill
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
17 Jul 2026, 17:51 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
The FDA has approved Merck's enlicitide (Lipfendra) as the first oral PCSK9 inhibitor to reduce LDL cholesterol in adults. — FDA approval of a first-in-class oral alternative to injectables represents a significant potential market share gain for Merck.
+0.60Lipfendra will be launched with a list price of $315 per month, which is significantly lower than competing injectable therapies from Amgen and Novartis. — Aggressive undercutting of prices puts downward pressure on the revenue and margins of competitors Repatha (Amgen) and Leqvio (Novartis).
-0.30Phase III studies showed that Lipfendra reduced LDL-C by 56% in hypercholesterolemia patients and 59% in HeFH patients versus placebo. — Strong clinical efficacy data supports the drug's potential for high adoption rates among clinicians and patients.
+0.30Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
FDA approval of Lipfendra, a first-of-its-kind oral PCSK9 inhibitor, is a significant positive catalyst for growth.
Faces new competition from Merck's Lipfendra, which is an oral formulation and expected to be priced significantly lower than Novartis's Leqvio.
Faces new competition from Merck's Lipfendra, which is an oral formulation and expected to be priced significantly lower than Amgen's Repatha.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
ETF Trends
37m ago
